Clinical trials: malaria, open to volunteers
Malaria
Safety, Tolerability, Pharmacokinetics, and Mosquitocidal Activity of Lotilaner in Healthy Participants in Mali.
This is a Phase 1b, single-cente, randomized, double-blind, placebo-controlled proof-of-concept study evaluating the safety, tolerability, pharmacokinetics and mosquitocidal activity of single oral doses of lotilaner in healthy…
- Trial name
- NCT07758985
- Testing
- Cohort 1 low dose lotilaner with a high-fat meal, Cohort 2 high dose lotilaner in fasted state, Cohort 3 high dose lotilaner with a high-fat meal
- Where
- Mali
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria
A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults
This is an open-label pharmacokinetic study in 24 healthy Thai participants. Participants will be admitted in the inpatient ward and each participant will attend a total of 4 visits, including one screening visit and three…
- Trial name
- APP (NCT07470424)
- Testing
- Piperaquine, Artesunate-pyronaridine (Pyramax), Piperaquine and artesunate-pyronaridine (Pyramax)
- Where
- Thailand
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Pregnancy, Malaria
Observational Study of the Safety of Intravenous Artesunate Treatment of Pregnant Women and Their Infants
This study is a prospective observational study in which a female patient who received IV Artesunate while pregnant can volunteer to provide information about her pregnancy and the outcome of her pregnancy.
- Trial name
- NCT05285735
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Amivas Inc.
Malaria, Intestinal Worms
Evaluation, Treatment and Monitoring of Patients With a Known or Suspected Parasitic Infection
The purpose of this study is to evaluate, treat and follow patients with parasitic infections. People with a known or suspected parasitic infection who are at least 1 year old may be enrolled.
- Conditions
- Malaria, Intestinal Worms, GI Protozoa, Echiniococcus
- Trial name
- NCT00001645
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali
Malaria caused by Plasmodium falciparum continues to be a global problem with devastating consequences. A greater understanding of the immunologic and parasitologic factors associated with infection and disease is badly needed…
- Trial name
- NCT01168271
- Where
- 2 sites in Mali
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria Vaccine
Integrating Malaria Vaccine With Seasonal Malaria Chemoprevention in West Africa
This is a multi-site, multi-disciplinary, Phase-4 two-arm cluster-randomised non-inferiority trial in Burkina Faso and Mali to evaluate the effectiveness and real-life impact of a novel integrated delivery strategy of the R21…
- Trial name
- IMVACS (NCT06860178)
- Testing
- Annual campaign of the 3-dose primary series vaccine R21/Matrix-M aligned with SMC distribution in children aged 3-59 months
- Where
- 2 sites in Burkina Faso, Mali
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Epicentre
Pharmacokinetics of Tafenoquine
Investigating the Pharmacokinetics of Tafenoquine in Healthy Papua New Guinean Children
Plasmodium vivax is the most geographically widespread malaria species and the second largest contributor to symptomatic malaria worldwide.
- Trial name
- NCT07052162
- Testing
- Single dose tafenoquine (10 mg/kg) given with water, Single dose tafenoquine (10 mg/kg) given with fat
- Where
- Papua New Guinea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Curtin University
Malaria (Plasmodium Falciparum)
Challenge Trial of PfSPZ-LARC2 Vaccine in Burkina Faso
This is a randomized, double-blind, placebo-controlled, Phase 1 trial of Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) malaria vaccine (Sanaria® PfSPZ-LARC2 Vaccine)…
- Trial name
- BFSPZL3 (NCT07730177)
- Testing
- PfSPZ-LARC2 Vaccine, PfSPZ Challenge, Normal Saline
- Where
- Burkina Faso
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria
Three-arm Cluster Randomised Control Trial Evaluation of Guardian Spatial Emanator as a Complimentary Vector Control Tool in Papua New Guinea
Malaria cases are increasing in Papua New Guinea, partly because insecticide-treated nets do not fully protect people, especially from mosquitoes that bite outdoors.
- Trial name
- WinMal (NCT07912528)
- Testing
- Spatial emanator outdoor, Spatial emanator indoor
- Where
- Papua New Guinea
- Volunteers
- 4,350 people, healthy volunteers welcome
- Sponsor
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Bacteremia
Surveillance of AMR in DRC
This study addresses knowledge gaps regarding antimicrobial resistance (AMR) in sub-Saharan Africa, focusing on evaluating the feasibility of AMR surveillance and enhancing local research capacity.
- Trial name
- SARKIN (NCT06821282)
- Where
- Democratic Republic of the Congo
- Volunteers
- 210 people
- Sponsor
- University of Oxford
Newborn Resuscitation, Severe Malnutrition
Enhancing Pediatric Acute Care Through Adaptive E-Learning and In-Person Skills Practice in Tanzania
The goal of this clinical trial is to evaluate whether the integration of in-person skills practice (ISP) with an adaptive e-learning platform can improve refresher learning progress (RLP) among healthcare providers in pediatric…
- Conditions
- Newborn Resuscitation, Severe Malnutrition, Severe Malaria, Severe Pneumonia
- Trial name
- PACE (NCT06635733)
- Testing
- Rhapsode Capable™ Platform (Intervention Group), Paper-based ISP (Control Group)
- Where
- Tanzania
- Volunteers
- 100 people
- Sponsor
- Stanford University
Malaria (Plasmodium Falciparum)
Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults
This is a phase 2 clinical trial of a Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) vaccine (Sanaria® PfSPZ-LARC2 Vaccine) that will assess field efficacy in Africa.
- Trial name
- BFSPZL2 (NCT07385287)
- Testing
- Genetically attenuated PfSPZ Vaccine, Normal Saline (0.9% Sodium Chloride)
- Where
- Burkina Faso
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria
Intermittent Preventive Treatment of Malaria in School-age Children to Decrease Community Transmission
The CRITICal study aims to estimate the effectiveness of intermittent preventive treatment in school children (IPTsc) with dihydroartemisinin-piperaquine (DP) for reducing community level malaria burden.
- Trial name
- CRITICal (NCT07246525)
- Testing
- dihydroartemisinin-piperaquine
- Where
- Uganda
- Volunteers
- 4,800 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Invasive Non-Typhoidal Salmonella Disease, Malaria
Effectiveness of Malaria Vaccines in Reducing the Risk of Invasive Non-typhoidal Salmonella Disease
The goal of this observational study is to learn about the impact of malaria vaccination on the risk of invasive non-typhoidal Salmonella disease in children below the age of 5.
- Conditions
- Invasive Non-Typhoidal Salmonella Disease, Malaria, Malaria Vaccine
- Trial name
- VINS (NCT07416461)
- Testing
- R21/Matrix-M malaria vaccine
- Where
- Democratic Republic of the Congo
- Volunteers
- 10,000 people
- Sponsor
- International Vaccine Institute
Malaria (Plasmodium Falciparum)
PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in Mali
A randomized double blind, placebo-controlled study to assess the safety, tolerability, immunogenicity, and protective efficacy of 1, 6, 29-day PfSPZ-LARC2 Vaccine regimen given at a dose of 2 x10^5 PfSPZ or placebo in healthy…
- Trial name
- NCT07675785
- Testing
- PfSPZ-LARC2 Vaccine, Normal Saline
- Where
- Mali
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)
This was Cohort C2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.
- Trial name
- PLATINUM (NCT07811908)
- Testing
- KAE609, SoC (Coartem), KLU156
- Where
- 13 sites in Burkina Faso, Côte d’Ivoire and 5 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Ovarian Cancer
Plasmodium Immunotherapy for Advanced Ovarian Cancer
The main purpose of this study is to evaluate the safety and effectiveness of Plasmodium immunotherapy in the treatment of advanced ovarian cancer. This study plans to enroll 30 patients with advanced ovarian cancer.
- Trial name
- NCT05924776
- Testing
- Plasmodium immunotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.
Malaria, PLASMODIUM FALCIPARUM MALARIA
Assessing Vaccine Effectiveness of R21/Matrix-M Across Malaria Transmission Settings (AVERT)
The AVERT study is a prospective observational test-negative case control study evaluating the real-world effectiveness of the R21/Matrix-M malaria vaccine among children younger than 5 years in Burkina Faso and Uganda.
- Trial name
- AVERT (NCT07749911)
- Testing
- R21/Matris-M Malaria vaccine
- Where
- 21 sites in Burkina Faso, Uganda
- Volunteers
- 20,000 people
- Sponsor
- Clinton Health Access Initiative Inc.
Malaria Falciparum, Malaria Infection
Experimental Malaria Infection of Healthy Malaria-Naive Adults by Mosquito Bite With the Genetically Modified Plasmodium Falciparum NF54/iGP3 GAP
The goal of this clinical trial is to learn if the genetically-modified malaria parasite NF54/iGP3 will safely infect humans with malaria.
- Conditions
- Malaria Falciparum, Malaria Infection, Malaria Transmission
- Trial name
- iGP3-SWITCH (NCT06881732)
- Testing
- NF54/iGP3
- Where
- Australia
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- University of Melbourne
Plasmodium Vivax Malaria, Malaria
FocaL Mass Drug Administration for Vivax Malaria Elimination
FLAME is an open-label cluster-randomized controlled trial that aims to determine the effectiveness of focal mass drug administration (fMDA) to reduce the incidence of Plasmodium vivax malaria in the Loreto Department in Peru.
- Trial name
- FLAME (NCT05690841)
- Testing
- Focal Mass Drug Administration (fMDA)
- Where
- Peru
- Volunteers
- 7,530 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco